Journal
INTERNATIONAL JOURNAL OF HEMATOLOGY
Volume 99, Issue 3, Pages 272-278Publisher
SPRINGER JAPAN KK
DOI: 10.1007/s12185-014-1503-4
Keywords
AML; Midostaurin; ATRA; Phase I; Targeted therapy; CLAG
Categories
Funding
- Novartis
Ask authors/readers for more resources
We conducted a phase I study using midostaurin (25 or 50 mg orally twice daily), all-trans retinoic acid (ATRA) and CLAG chemotherapy to target multiple pathways in relapsed/refractory AML. 10 patients received the combination and no dose-limiting toxicities were observed. Two patients (22 %) achieved complete remission and 1 patient (11 %) achieved complete remission with incomplete count recovery. Pharmacokinetic data showed that the 25 mg dosing of midostaurin achieved therapeutic levels with no significant interaction between midostaurin and ATRA. With evidence of activity of ATRA in NPM1-mutated AML and midostaurin in FLT3-ITD AML, this combination warrants further investigation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available